Harrow to Acquire Tyrvaya Dry Eye Treatment from Viatris in Deal Worth Up to $100 Million

Key Facts

In a move reflecting the strategic expansion within the ophthalmic pharmaceutical sector, Harrow has entered into a definitive agreement to acquire Tyrvaya nasal spray for dry eye treatment from Viatris Inc. According to reports, the deal structure involves a $30 million upfront cash payment and up to $70 million in contingent milestone payments. This acquisition is designed to strengthen Harrow's position in the dry eye disease market by adding a treatment with a distinct mechanism of action to complement its existing Vevye franchise.

This strategic shift occurs as mid-cap pharmaceutical firms increasingly seek to bolster their core portfolios through targeted asset acquisitions. Per market analysis, the deal represents a bullish development for Harrow, providing a clear financial path to expanding its specialized offerings. The acquisition allows the company to integrate a unique therapeutic asset while managing financial risk through the milestone-based payment structure.

Market participants should also watch for broader economic catalysts, such as the upcoming Michigan Consumer Sentiment and inflation expectations data from the US, which may influence sector-wide sentiment.